137. Focal cortical dysplasia Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 9 / Drugs : 5 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 51
Drugs and their primary sponsors and trial info
Afinitor (everolimus)
Yonsei University
2018 Phase 2 NCT03198949 Korea, Republic of;
Classical ketogenic diet
University College, London
2014 - NCT02261753 Austria;Belgium;Czech Republic;Czechia;France;Germany;Italy;Switzerland;United Kingdom;United States;
Everolimus
NYU Langone Health
2014 Phase 2 NCT02451696 United States;
Gold
Beijing Tiantan Hospital, Capital Medical University
2020 Phase 0 ChiCTR2100046183 China;
Sirolimus
Hokkaido University Hospital
2018 - JPRN-UMIN000030962 Japan;
Hokkaido University HospitalNishi-Niigata Chuo National HospitalNational Center Hospital, NCNPShizuoka Institute of Epilepsy and Neurological DisordersOkayama University Hospital
2018 Phase 2 JPRN-UMIN000033504 Japan;
Kato Mitsuhiro
2019 Phase 2 JPRN-jRCTs031190157 Japan;
National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO
2017 Phase 2 JPRN-UMIN000030797 Japan;
Takahashi Yukitoshi
2019 Phase 2 JPRN-jRCTs041190059 Japan;
Yonsei University
2018 Phase 2 NCT03198949 Korea, Republic of;
Classical ketogenic diet
University College, London
2014 - NCT02261753 Austria;Belgium;Czech Republic;Czechia;France;Germany;Italy;Switzerland;United Kingdom;United States;
Everolimus
NYU Langone Health
2014 Phase 2 NCT02451696 United States;
Gold
Beijing Tiantan Hospital, Capital Medical University
2020 Phase 0 ChiCTR2100046183 China;
Sirolimus
Hokkaido University Hospital
2018 - JPRN-UMIN000030962 Japan;
Hokkaido University HospitalNishi-Niigata Chuo National HospitalNational Center Hospital, NCNPShizuoka Institute of Epilepsy and Neurological DisordersOkayama University Hospital
2018 Phase 2 JPRN-UMIN000033504 Japan;
Kato Mitsuhiro
2019 Phase 2 JPRN-jRCTs031190157 Japan;
National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO
2017 Phase 2 JPRN-UMIN000030797 Japan;
Takahashi Yukitoshi
2019 Phase 2 JPRN-jRCTs041190059 Japan;